Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma - Wikidata - awgldk - TriplyDB

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

http://www.wikidata.org/entity/Q36936514

about

Bortezomib for the treatment of multiple myeloma Multiple myeloma in the very elderly patient: challenges and solutions Subcutaneous Administration of Bortezomib: A Pilot Survey of Oncology Nurses Spotlight on ixazomib: potential in the treatment of multiple myeloma Clinical use of proteasome inhibitors in the treatment of multiple myeloma Current and emerging therapies in mantle cell lymphoma.A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma.Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib.Subcutaneous administration of bortezomib: strategies to reduce injection site reactions.Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma.Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection.A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma.Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide.A phase II trial of small-dose bortezomib, lenalidomide and dexamethasone (sVRD) as consolidation/maintenance therapy in patients with multiple myeloma.Subcutaneous bortezomib: in multiple myeloma.Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences.An analysis of the safety profile of proteasome inhibitors for treating various cancers.Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.Impact of concomitant dexamethasone dosing schedule on bortezomib-induced peripheral neuropathy in multiple myeloma.Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.Safety of proteasome inhibitors for treatment of multiple myeloma.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.An Overview of Bortezomib-Induced Neurotoxicity Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.Characterization of a rat model of bortezomib-induced painful neuropathy.Proteasome-associated deubiquitinases and cancer.The proteasome and proteasome inhibitors in multiple myeloma.Bortezomib for the treatment of multiple myeloma.

P2860

Q24185881-42DDC985-F2F7-4DF3-935D-25E5D085E78F Q26752991-EDE7488F-D1C3-4A34-9223-7547C365E79E Q26771947-C1A16136-7347-459F-8796-D3E41AFCD16C Q26774440-9E8E8404-4A63-43D9-81F5-B5F0FB2D13BC Q28080999-6DB06822-DF10-4909-90F8-1B153F6329D9 Q30456545-0985DC1C-4D54-4746-813B-128A4F25B2AD Q33402536-ABB8C65D-8016-4AD7-A492-F4553F71131B Q33404348-B2BA8F89-949B-4A1B-BF59-6F8F6C784A19 Q33404749-1106FC03-1D81-4BEB-A2E0-7AFA1CE0CB59 Q33405134-B8283A10-D5BB-4A8A-8C0E-55705FE9A204 Q33408056-1D2F3D97-F650-4138-8666-6889755943A8 Q33412684-563F24D6-22D0-4B5D-8A31-46DA070B795A Q33422017-6FE47C54-7735-4887-89B6-32198000D36D Q33437045-1D80C56F-368F-4CBE-998F-E80D843898A4 Q33440605-30EDB299-4B19-451A-971D-BA3BB0D3E56C Q33885696-2488C7DE-90EC-400D-8ED0-5BE5966A5ED3 Q34798095-EB6E695F-55CE-4BB9-A9AC-B2E781500723 Q34990174-204F3862-A309-4409-827B-19B16E64D41B Q35800851-A4F9D9FB-18B9-46DD-AC45-1788F80CC01E Q35827701-EB988A5E-343D-4ACD-8B04-B4060D54B4A2 Q36037229-0407782F-DEBB-4F4B-8DFA-68ED6FD77BF7 Q36302859-DFA9B54F-B92F-45E5-BD03-28528051FFC3 Q37064721-11C89932-4225-48E0-89BC-E25443622896 Q37373159-44DC0051-897A-48F1-A5B3-3EB89062D0E9 Q38075800-CA89725D-CA51-4CA8-B2EC-6B4C9EEF2097 Q38164689-2BD00B21-A620-418D-906C-D00A1148D3B1 Q38227506-7EB02620-4D7C-4082-A9FB-78D49BCD645E Q38232055-7C1A4180-1230-4D8E-BF3A-093DDF226494 Q38738098-636C0570-60C4-4CC7-B2B3-6B18D68414C2 Q38757067-7D876389-1DF1-4E16-AF3D-BD9EFFB383B4 Q39007504-2895003A-0FF8-41DC-A28F-3105F83F23B7 Q39177792-BBA47B34-FD86-4381-B9E1-CCA4A7155463 Q42046604-A045A1D3-6097-46C1-B26C-9B83D195A976 Q42335813-E9A68069-5E10-4085-9DA7-134A52FE6326 Q42361419-9436BCBE-48BA-41E0-BCE6-24BC0D24CB13 Q42573839-95E06686-E9E7-46CC-930F-61A8DFD66AA0 Q47120603-6A819F9A-D9B2-4018-A937-5E9F226917C9 Q47161331-6CE19877-0B68-4EE5-B706-38E9632137D6 Q47339695-3129A4E4-A791-4F22-99E0-E6A52B35CE77 Q47604607-3AAE7D5D-E320-44B3-ACD1-B0B47EDFBCFB

P2860

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

http://www.wikidata.org/entity/Q36936514

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Updated survival analysis of a ...... with relapsed multiple myeloma

@en

type

label

Updated survival analysis of a ...... with relapsed multiple myeloma

@en

prefLabel

Updated survival analysis of a ...... with relapsed multiple myeloma

@en

P1433

Q36936514-4E4A6DB8-DAA6-498D-A2AA-AFA4849C6BF1

P1476

Q36936514-D4EBE57B-5A13-4E7F-A7DC-40F1D88AF0C0

P2093

Q36936514-18889FE7-7AD5-44F0-83CC-C47D3512772A

Q36936514-4B6BA0F8-2D27-4576-B371-8C59885B37EE

Q36936514-8ECECD57-7489-4C57-AF9A-420A85D06FDF

Q36936514-954EB702-41F9-44A3-9A00-36C8B54B63BE

Q36936514-CD152B25-2636-4AD5-9041-53122FB73F77

Q36936514-DEA74086-C46B-46E3-AB86-2BC475163FBD

Q36936514-E82091E9-C33F-4D2D-B646-EEB4A8198C31

Q36936514-F15BB670-60F3-4ACB-A919-C68430F20996

P2860

Q36936514-1C75C363-389B-4E8B-AFA3-AD21D7348F4F

Q36936514-542A5C7B-D17D-4611-9EF7-38A353E7E92C

Q36936514-5E93733F-1B0E-4C1E-92F8-8FDD888DBCDE

Q36936514-7BCE2257-13B4-45D1-A0C2-714E413E9D44

Q36936514-7D5B6526-EA93-49BB-B402-A8279891E825

Q36936514-820E9066-C58C-4DF1-88AD-95B65FEB6C5B

Q36936514-8A4E1A0D-927A-4B26-ABFD-F2BAEF48575C

Q36936514-8C15D6C2-F931-485C-B179-4AECADF10B2C

Q36936514-8E9C7046-A455-471C-B10E-7EF035C5DC01

Q36936514-950729B7-4D33-450F-91F0-68F85835ED5E

P304

Q36936514-D7ED975C-45B9-41FD-946F-5DE994E97288

P31

Q36936514-A653B9E7-4D3F-432B-9ADD-63D3DAAAD016

P356

Q36936514-03873BB0-F8F7-495F-9AA7-14313E03F972

P433

Q36936514-15F4E59D-52F6-41DE-B526-15CA4E05FEDA

P478

Q36936514-66DA0910-E580-4D46-9BA0-1FDF024B9C1A

P50

Q36936514-5CE63DD0-9CA0-46A3-A363-8B4F0150BC91

Q36936514-61F5655B-07E3-4B98-8D98-C764E1F929C5

P577

Q36936514-02DA94B7-A921-48F9-8A9D-467A5D883AC2

P5875

Q36936514-4E0D3501-0E0D-4C1C-81F6-A3783E754E44

P698

Q36936514-DD357094-E68F-4306-B173-24475F28D1F5

P932

Q36936514-DCE9D4A4-B2F4-45C4-B98D-36A71DB850A5

P356

HAEMATOL.2012.067793

P1433

P1476

Updated survival analysis of a ...... with relapsed multiple myeloma

@en

P2093

Andrew Cakana

http://www.w3.org/2001/XMLSchema#string

Bertrand Arnulf

http://www.w3.org/2001/XMLSchema#string

Halyna Pylypenko

http://www.w3.org/2001/XMLSchema#string

Helgi van de Velde

http://www.w3.org/2001/XMLSchema#string

Huaibao Feng

http://www.w3.org/2001/XMLSchema#string

Ievgenii Karamanesht

http://www.w3.org/2001/XMLSchema#string

Sebastian Grosicki

http://www.w3.org/2001/XMLSchema#string

William Deraedt

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

International staging system for multiple myeloma.

International uniform response criteria for multiple myeloma.

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Treatment of relapsed and refractory multiple myeloma in the era of novel agents.

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

P304

1925-1928

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2012.067793

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P50

Philippe Moreau

P577

2012-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225293484

http://www.w3.org/2001/XMLSchema#string

P698

22689676

http://www.w3.org/2001/XMLSchema#string

P932

3685287

http://www.w3.org/2001/XMLSchema#string